Metastatic Pancreatic Cancer
Conditions
Keywords
Pancreatic, Pancreatic Cancer, Lenalidomide, Revlimid, Gemcitabine
Brief summary
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
Detailed description
Because the activity of lenalidomide addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - lenalidomide is being evaluated as part of induction chemotherapy regimens for solid tumors. This phase II study in previously untreated metastatic pancreatic cancer is designed to establish and test the appropriate lenalidomide dose and regimen in combination with gemcitabine.
Interventions
DRUGGemcitabine
Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
DRUGLenalidomide
The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
Sponsors
Celgene Corporation
SCRI Development Innovations, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understand and voluntarily sign the informed consent form. 2. Patients \>=18 years of age at the time of signing the informed consent form. 3. Ability to adhere to the study visit schedule and other protocol requirements. 4. Histological or cytological documentation of adenocarcinoma of the pancreas, with metastases not amenable to curative surgery or definitive radiation. Patients with locally advanced disease are not eligible. 5. Radiographic or clinical evidence of measurable advanced metastatic pancreatic carcinoma. Patients must have measurable disease according to the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) for target lesions. 6. Previous gemcitabine or 5-fluorouracil (5-FU) with radiation therapy as adjuvant therapy is permitted. Extended use of gemcitabine or 5-FU after completion of adjuvant radiation therapy is not permitted. No prior gemcitabine for metastatic disease or for primary treatment of locally advanced disease is allowed. 7. ECOG performance status of \<=2 at study entry. 8. Laboratory test results within these ranges: * Absolute neutrophil count (ANC) ≥1,500 cells/mm3 (1.5 x 109/L) * Platelet count ≥100,000 cells/ mm3 (100 x 109/L) * Serum creatinine \<=2.5 mg/dL * Total bilirubin \<=2.0 mg/dL * AST (SGOT) and ALT (SGPT) \<=3.0 x ULN or \<=5 x ULN if hepatic metastases are present. 9. Prior history of malignancy (except basal cell or squamous cell carcinoma or carcinoma in situ of the cervix or breast, or localized prostate cancer with PSA \<1.0 ng/mL), unless the patient has been free of disease for \>=3 years. 10. All study participants must be registered into the mandatory RevAssist® program, and must be willing and able to comply with the requirements of RevAssist®.
Exclusion criteria
1. Prior use of systemic therapy for the treatment of adenocarcinoma of the pancreas, with the exception of 5-fluorouracil or gemcitabine as a radiosensitizer in the adjuvant setting. 2. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form. 3. Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide). 4. Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 5. Surgery or radiation therapy within 14 days of study enrollment as outlined below. * Surgery within 14 days of the start of study (patients must have recovered from effects of surgery; 7 days may be considered for minor procedures). * Palliative radiation therapy within 14 days of the start of study. The radiation therapy may not be to the only site of measurable disease. 6. Known brain or leptomeningeal disease (CT scan or MRI of the brain required only in case of clinical suspicion of central nervous system involvement). 7. Neuropathy of ≥ grade 2. 8. Known chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment | 6 months | The percentage of patients who were alive 6 months after beginning treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease | 18 months | The length of time, in months, that patients were alive from their first date of protocol treatment until worsening of their disease |
| Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death | 18 months | Length of time, in months, that patients were alive from their first date of protocol treatment until death |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lenalidomide/Gemcitabine The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15). After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred. | 72 |
| Total | 72 |
Baseline characteristics
| Characteristic | Lenalidomide/Gemcitabine |
|---|---|
| Age Continuous | 64 years |
| Region of Enrollment United States | 72 participants |
| Sex: Female, Male Female | 23 Participants |
| Sex: Female, Male Male | 49 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 71 / 72 |
| serious Total, serious adverse events | 8 / 72 |
Outcome results
Primary
Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment
The percentage of patients who were alive 6 months after beginning treatment
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenalidomide/Gemcitabine | Six-Month Overall Survival (OS) Probability, the Percentage of Patients Estimated to be Alive Six Months After Beginning Protocol Treatment | 37 percentage of participants |
Secondary
Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
Length of time, in months, that patients were alive from their first date of protocol treatment until death
Time frame: 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenalidomide/Gemcitabine | Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death | 4.7 months |
Secondary
Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
The length of time, in months, that patients were alive from their first date of protocol treatment until worsening of their disease
Time frame: 18 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenalidomide/Gemcitabine | Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease | 2.3 months |